{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T04:29:44Z","timestamp":1774412984238,"version":"3.50.1"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2025,5,12]],"date-time":"2025-05-12T00:00:00Z","timestamp":1747008000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,5,12]],"date-time":"2025-05-12T00:00:00Z","timestamp":1747008000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100018904","name":"Beijing Xisike Clinical Oncology Research Foundation","doi-asserted-by":"publisher","award":["Y-2019Genecast-024"],"award-info":[{"award-number":["Y-2019Genecast-024"]}],"id":[{"id":"10.13039\/100018904","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Hunan Cancer Hospital Climb plan","award":["ZX2020005-5"],"award-info":[{"award-number":["ZX2020005-5"]}]},{"name":"The science and technology innovation Program of Hunan Province","award":["2023SK4024"],"award-info":[{"award-number":["2023SK4024"]}]},{"name":"The science and technology innovation Program of Hunan Province","award":["2021SK51121"],"award-info":[{"award-number":["2021SK51121"]}]},{"name":"Hunan Lung Cancer Clinical Medical Research Center","award":["2023SK4024"],"award-info":[{"award-number":["2023SK4024"]}]},{"DOI":"10.13039\/501100004735","name":"Hunan Provincial Natural Science Foundation of China","doi-asserted-by":"crossref","award":["2021JJ30430"],"award-info":[{"award-number":["2021JJ30430"]}],"id":[{"id":"10.13039\/501100004735","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2025,7]]},"DOI":"10.1007\/s12325-025-03170-2","type":"journal-article","created":{"date-parts":[[2025,5,12]],"date-time":"2025-05-12T07:05:22Z","timestamp":1747033522000},"page":"3249-3264","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Anlotinib Plus Docetaxel is Promising in Advanced NSCLC Progressing on First-Line Immunotherapy: A Pooled Analysis of Two Randomized Trials"],"prefix":"10.1007","volume":"42","author":[{"given":"Xingxiang","family":"Pu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiawei","family":"Shou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zemin","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jun","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maoliang","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qunyi","family":"Guo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhongxia","family":"Ma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei","family":"Hong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qianzhi","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yonghui","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jia","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chuangzhou","family":"Rao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jie","family":"Weng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liqin","family":"Lu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lin","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yong","family":"Fang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,5,12]]},"reference":[{"key":"3170_CR1","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1038\/s41571-021-00520-1","volume":"18","author":"MJ Grant","year":"2021","unstructured":"Grant MJ, Herbst RS, Goldberg SB. Selecting the optimal immunotherapy regimen in driver-negative metastatic NSCLC. Nat Rev Clin Oncol. 2021;18:625\u201344.","journal-title":"Nat Rev Clin Oncol"},{"key":"3170_CR2","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1186\/s12943-020-01260-z","volume":"19","author":"L Horvath","year":"2020","unstructured":"Horvath L, Thienpont B, Zhao L, Wolf D, Pircher A. Overcoming immunotherapy resistance in non-small cell lung cancer (NSCLC)\u2014novel approaches and future outlook. Mol Cancer. 2020;19:141.","journal-title":"Mol Cancer"},{"key":"3170_CR3","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2023.100879","volume":"8","author":"L Moliner","year":"2023","unstructured":"Moliner L, Spurgeon L, Califano R. Controversies in NSCLC: which second-line strategy after chemo-immunotherapy? ESMO Open. 2023;8: 100879.","journal-title":"ESMO Open"},{"key":"3170_CR4","doi-asserted-by":"publisher","first-page":"2699","DOI":"10.2217\/fon-2019-0262","volume":"15","author":"C Groh\u00e9","year":"2019","unstructured":"Groh\u00e9 C, Gleiber W, Haas S, et al. Nintedanib plus docetaxel after progression on immune checkpoint inhibitor therapy: insights from VARGADO, a prospective study in patients with lung adenocarcinoma. Future Oncol. 2019;15:2699\u2013706.","journal-title":"Future Oncol"},{"key":"3170_CR5","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.lungcan.2020.04.021","volume":"144","author":"T Tozuka","year":"2020","unstructured":"Tozuka T, Kitazono S, Sakamoto H, et al. Addition of ramucirumab enhances docetaxel efficacy in patients who had received anti-PD-1\/PD-L1 treatment. Lung Cancer. 2020;144:71\u20135.","journal-title":"Lung Cancer"},{"key":"3170_CR6","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1111\/1759-7714.14236","volume":"13","author":"M Ishida","year":"2022","unstructured":"Ishida M, Morimoto K, Yamada T, et al. Impact of docetaxel plus ramucirumab in a second-line setting after chemoimmunotherapy in patients with non-small-cell lung cancer: a retrospective study. Thorac Cancer. 2022;13:173\u201381.","journal-title":"Thorac Cancer"},{"key":"3170_CR7","doi-asserted-by":"publisher","first-page":"2295","DOI":"10.1200\/JCO.22.00912","volume":"40","author":"KL Reckamp","year":"2022","unstructured":"Reckamp KL, Redman MW, Dragnev KH, et al. Phase II randomized study of ramucirumab and pembrolizumab versus standard of care in advanced non-small-cell lung cancer previously treated with immunotherapy-lung-MAP S1800A. J Clin Oncol. 2022;40:2295\u2013306.","journal-title":"J Clin Oncol"},{"key":"3170_CR8","doi-asserted-by":"publisher","first-page":"S121","DOI":"10.1016\/j.jtho.2022.07.201","volume":"17","author":"M Reck","year":"2022","unstructured":"Reck M, Sadjadian P, Waller C, et al. P1.15\u201305 Nintedanib in Combination with Nivolumab in Pretreated patients with advanced adenocarcinoma of the lung (AIO-TRK-0117 phase IB\/II trial). J Thorac Oncol. 2022;17:S121.","journal-title":"J Thorac Oncol"},{"key":"3170_CR9","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.AM2020-CT289","volume":"80","author":"NB Leighl","year":"2020","unstructured":"Leighl NB, Hui R, Rodr\u00edguez-Abreu D, et al. Abstract CT289: Pembrolizumab plus lenvatinib vs docetaxel in patients with previously treated metastatic non-small-cell lung cancer (NSCLC) and PD after platinum-doublet chemotherapy and immunotherapy: Phase 3, randomized, open-label LEAP-008 trial. Cancer Res. 2020;80: CT289-CT.","journal-title":"Cancer Res"},{"key":"3170_CR10","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/j.lungcan.2020.04.009","volume":"144","author":"S Popat","year":"2020","unstructured":"Popat S, Groh\u00e9 C, Corral J, et al. Anti-angiogenic agents in the age of resistance to immune checkpoint inhibitors: Do they have a role in non-oncogene-addicted non-small cell lung cancer? Lung Cancer. 2020;144:76\u201384.","journal-title":"Lung Cancer"},{"key":"3170_CR11","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1016\/j.jtho.2016.10.003","volume":"12","author":"C Manegold","year":"2017","unstructured":"Manegold C, Dingemans AC, Gray JE, et al. The potential of combined immunotherapy and antiangiogenesis for the synergistic treatment of advanced NSCLC. J Thorac Oncol. 2017;12:194\u2013207.","journal-title":"J Thorac Oncol"},{"key":"3170_CR12","doi-asserted-by":"publisher","first-page":"1057","DOI":"10.1007\/s40265-018-0939-x","volume":"78","author":"YY Syed","year":"2018","unstructured":"Syed YY. Anlotinib: first global approval. Drugs. 2018;78:1057\u201362.","journal-title":"Drugs"},{"key":"3170_CR13","doi-asserted-by":"publisher","first-page":"1569","DOI":"10.1001\/jamaoncol.2018.3039","volume":"4","author":"B Han","year":"2018","unstructured":"Han B, Li K, Wang Q, et al. Effect of anlotinib as a third-line or further treatment on overall survival of patients with advanced non-small cell lung cancer: the ALTER 0303 Phase 3 randomized clinical trial. JAMA Oncol. 2018;4:1569\u201375.","journal-title":"JAMA Oncol"},{"key":"3170_CR14","first-page":"S1021","volume":"32","author":"Y Fang","year":"2021","unstructured":"Fang Y, Pan H, Shou J, et al. 1335P updated results from a phase I\/II study of anlotinib plus docetaxel vs docetaxel as second-line treatment of advanced non-small cell lung cancer (NSCLC). Ann Oncol. 2021;32:S1021.","journal-title":"Ann Oncol"},{"key":"3170_CR15","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2024.107538","volume":"191","author":"X Pu","year":"2024","unstructured":"Pu X, Xiao Z, Li J, et al. Anlotinib plus docetaxel vs. docetaxel alone for advanced non-small-cell lung cancer patients who failed first-line treatment: a multicenter, randomized phase II trial. Lung Cancer. 2024;191: 107538.","journal-title":"Lung Cancer"},{"key":"3170_CR16","doi-asserted-by":"publisher","first-page":"3093","DOI":"10.21037\/tlcr-21-197","volume":"10","author":"WM Brueckl","year":"2021","unstructured":"Brueckl WM, Reck M, Rittmeyer A, et al. Efficacy of docetaxel plus ramucirumab as palliative second-line therapy following first-line chemotherapy plus immune-checkpoint-inhibitor combination treatment in patients with non-small cell lung cancer (NSCLC) UICC stage IV. Transl Lung Cancer Res. 2021;10:3093\u2013105.","journal-title":"Transl Lung Cancer Res"},{"key":"3170_CR17","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1111\/1759-7714.12998","volume":"10","author":"A Shiono","year":"2019","unstructured":"Shiono A, Kaira K, Mouri A, et al. Improved efficacy of ramucirumab plus docetaxel after nivolumab failure in previously treated non-small cell lung cancer patients. Thorac Cancer. 2019;10:775\u201381.","journal-title":"Thorac Cancer"},{"key":"3170_CR18","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2023.102303","volume":"66","author":"R Matsuzawa","year":"2023","unstructured":"Matsuzawa R, Morise M, Ito K, et al. Efficacy and safety of second-line therapy of docetaxel plus ramucirumab after first-line platinum-based chemotherapy plus immune checkpoint inhibitors in non-small cell lung cancer (SCORPION): a multicenter, open-label, single-arm, phase 2 trial. EClinicalMedicine. 2023;66: 102303.","journal-title":"EClinicalMedicine"},{"key":"3170_CR19","doi-asserted-by":"publisher","first-page":"2010","DOI":"10.21037\/tlcr-21-1018","volume":"11","author":"C Groh\u00e9","year":"2022","unstructured":"Groh\u00e9 C, Wehler T, Dechow T, et al. Nintedanib plus docetaxel after progression on first-line immunochemotherapy in patients with lung adenocarcinoma: Cohort C of the non-interventional study, VARGADO. Transl Lung Cancer Res. 2022;11:2010\u201321.","journal-title":"Transl Lung Cancer Res"},{"key":"3170_CR20","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/j.lungcan.2020.08.004","volume":"148","author":"M Reck","year":"2020","unstructured":"Reck M, Syrigos K, Miliauskas S, et al. Non-interventional LUME-BioNIS study of nintedanib plus docetaxel after chemotherapy in adenocarcinoma non-small cell lung cancer: a subgroup analysis in patients with prior immunotherapy. Lung Cancer. 2020;148:159\u201365.","journal-title":"Lung Cancer"},{"key":"3170_CR21","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1016\/j.clon.2021.12.010","volume":"34","author":"C Grohe","year":"2022","unstructured":"Grohe C, Blau W, Gleiber W, et al. Real-world efficacy of nintedanib plus docetaxel after progression on immune checkpoint inhibitors: results from the ongoing, non-interventional VARGADO study. Clin Oncol (R Coll Radiol). 2022;34:459\u201368.","journal-title":"Clin Oncol (R Coll Radiol)"},{"key":"3170_CR22","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1038\/nrclinonc.2018.29","volume":"15","author":"D Fukumura","year":"2018","unstructured":"Fukumura D, Kloepper J, Amoozgar Z, Duda DG, Jain RK. Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges. Nat Rev Clin Oncol. 2018;15:325\u201340.","journal-title":"Nat Rev Clin Oncol"},{"key":"3170_CR23","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aak9679","volume":"9","author":"E Allen","year":"2017","unstructured":"Allen E, Jabouille A, Rivera LB, et al. Combined antiangiogenic and anti-PD-L1 therapy stimulates tumor immunity through HEV formation. Sci Transl Med. 2017;9: eaak9679.","journal-title":"Sci Transl Med"},{"key":"3170_CR24","doi-asserted-by":"publisher","first-page":"1909","DOI":"10.1016\/j.jtho.2021.07.009","volume":"16","author":"MA Socinski","year":"2021","unstructured":"Socinski MA, Nishio M, Jotte RM, et al. IMpower150 final overall survival analyses for atezolizumab plus bevacizumab and chemotherapy in first-line metastatic nonsquamous NSCLC. J Thorac Oncol. 2021;16:1909\u201324.","journal-title":"J Thorac Oncol"},{"key":"3170_CR25","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1016\/j.jtho.2017.10.011","volume":"13","author":"SE Park","year":"2018","unstructured":"Park SE, Lee SH, Ahn JS, Ahn MJ, Park K, Sun JM. Increased response rates to salvage chemotherapy administered after PD-1\/PD-L1 inhibitors in patients with non-small cell lung cancer. J Thorac Oncol. 2018;13:106\u201311.","journal-title":"J Thorac Oncol"},{"key":"3170_CR26","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.lungcan.2017.07.034","volume":"112","author":"G Schvartsman","year":"2017","unstructured":"Schvartsman G, Peng SA, Bis G, et al. Response rates to single-agent chemotherapy after exposure to immune checkpoint inhibitors in advanced non-small cell lung cancer. Lung Cancer. 2017;112:90\u20135.","journal-title":"Lung Cancer"},{"key":"3170_CR27","volume":"3","author":"S Xu","year":"2022","unstructured":"Xu S, Shukuya T, Tamura J, et al. Heterogeneous outcomes of immune checkpoint inhibitor rechallenge in patients with NSCLC: a systematic review and meta-analysis. JTO Clin Res Rep. 2022;3: 100309.","journal-title":"JTO Clin Res Rep"},{"key":"3170_CR28","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1158\/1078-0432.CCR-21-2241","volume":"28","author":"Y Su","year":"2022","unstructured":"Su Y, Luo B, Lu Y, et al. Anlotinib induces a T cell-inflamed tumor microenvironment by facilitating vessel normalization and enhances the efficacy of PD-1 checkpoint blockade in neuroblastoma. Clin Cancer Res. 2022;28:793\u2013809.","journal-title":"Clin Cancer Res"},{"key":"3170_CR29","doi-asserted-by":"publisher","first-page":"2300141","DOI":"10.1002\/adtp.202300141","volume":"6","author":"B Zou","year":"2023","unstructured":"Zou B, Jiang H, Liu H, et al. Anlotinib combined with anti-PD1 potentiates anti-tumor immunity via immunogenic cell death and macrophage reprogramming. Adv Ther. 2023;6:2300141.","journal-title":"Adv Ther"},{"key":"3170_CR30","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/j.lungcan.2020.04.009","volume":"144","author":"S Popat","year":"2020","unstructured":"Popat S, Grohe C, Corral J, et al. Anti-angiogenic agents in the age of resistance to immune checkpoint inhibitors: Do they have a role in non-oncogene-addicted non-small cell lung cancer? Lung Cancer. 2020;144:76\u201384.","journal-title":"Lung Cancer"},{"key":"3170_CR31","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1016\/S0140-6736(16)32517-X","volume":"389","author":"A Rittmeyer","year":"2017","unstructured":"Rittmeyer A, Barlesi F, Waterkamp D, et al. Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial. Lancet. 2017;389:255\u201365.","journal-title":"Lancet"},{"key":"3170_CR32","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1016\/j.lungcan.2021.08.006","volume":"160","author":"N Zhou","year":"2021","unstructured":"Zhou N, Jiang M, Li T, et al. Anlotinib combined with anti-PD-1 antibody, camrelizumab for advanced NSCLCs after multiple lines treatment: An open-label, dose escalation and expansion study. Lung Cancer. 2021;160:111\u20137.","journal-title":"Lung Cancer"},{"key":"3170_CR33","doi-asserted-by":"publisher","first-page":"8015","DOI":"10.1200\/jco.2013.31.15_suppl.8015","volume":"31","author":"L Zhang","year":"2013","unstructured":"Zhang L, Lu S, Cheng Y, et al. Different-dose docetaxel plus cisplatin as first-line chemotherapy and then maintenance therapy with single-agent docetaxel for advanced non-small cell lung cancer (TFINE study, C-TONG 0904). J Clin Oncol. 2013;31:8015.","journal-title":"J Clin Oncol"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-025-03170-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-025-03170-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-025-03170-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,21]],"date-time":"2025-06-21T08:14:26Z","timestamp":1750493666000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-025-03170-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,12]]},"references-count":33,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2025,7]]}},"alternative-id":["3170"],"URL":"https:\/\/doi.org\/10.1007\/s12325-025-03170-2","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,12]]},"assertion":[{"value":"31 October 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 March 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 May 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Xingxiang Pu, Jiawei Shou, Zemin Xiao, Jun Chen, Maoliang Xiao, Qunyi Guo, Zhongxia Ma, Wei Hong, Qianzhi Wang, Yonghui Wang, Jia Li, Chuangzhou Rao, Jie Weng, Liqin Lu, Lin Wu, and Yong Fang have nothing to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"Central approvals for ALTER-L016 and ALTER-L018 trials were obtained from the institutional review boards of leading centers (Sir Run Run Shaw Hospital, Zhejiang University School of Medicine; Hunan Cancer Hospital, The Affiliated Cancer Hospital of Xiangya School of Medicine). The study was conducted in accordance with the ethical principles listed in the Declaration of Helsinki. All patients in both trials provided written informed consent.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}